Investigational drug · Phase 2
TollB-001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TollB-001"
First trial start
2025
Sep 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TollB-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis (RA)
- Systemic Sclerosis (SSc)
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "TollB-001" as an intervention, largest first.
Toll Biotech Co. Ltd. (Beijing)Industry
NCT06103773 · 98 participants · Start Sep 28, 2023 · Primary completion Apr 7, 2025
Drug: TollB-001 tablets; TollB-001 placebo · For: Rheumatoid Arthritis
Sites: Chengdu, China
- A Phase II Study of TollB-001 Tablets in Systemic SclerosisNot yet recruiting
Toll Biotech Co. Ltd. (Beijing)Industry
NCT07745725 · 36 participants (planned) · Start Aug 2026 · Primary completion Oct 2027
Drug: TollB-001 Tablet; Placebo · For: Systemic Sclerosis (SSc)
Sites: Beijing, China · 2 sites in all
Toll Biotech Co. Ltd. (Beijing)Industry
NCT07408024 · 24 participants (planned) · Start Sep 10, 2025 · Primary completion Dec 2026
Drug: TollB-001; Placebo · For: Rheumatoid Arthritis (RA)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Advances and challenges in Toll-like receptor-targeted therapy for rheumatoid arthritis.
Xu XY, Guo SN, Li J · Drug Discov Today 2026
Also in development for Rheumatoid Arthritis (RA)
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
Beijing VDJBio Co., LTD. · Anti IL-6R, Idiopathic Multicentric Castleman's Disease, Castleman's Disease, Multicentric
- proposed biosimilar to etanerceptMB04Phase 31 trial
mAbxience Research S.L. · Rheumatoid Arthritis (RA)
- AP1189Phase 23 trials
SynAct Pharma Aps · Rheumatoid Arthritis (RA), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
- JAB-8263Phase 22 trials
Jacobio Pharmaceuticals Co., Ltd. · Rheumatoid Arthritis (RA), NSCLC, SCLC
- FT839Phase 21 trial
Fate Therapeutics · ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Rheumatoid Arthritis (RA)
- QEL-005Phase 21 trial
Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.